inositol has been researched along with Glomerulosclerosis, Focal Segmental in 1 studies
Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.
inositol : Any cyclohexane-1,2,3,4,5,6-hexol.
1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.
muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.
Glomerulosclerosis, Focal Segmental: A clinicopathological syndrome or diagnostic term for a type of glomerular injury that has multiple causes, primary or secondary. Clinical features include PROTEINURIA, reduced GLOMERULAR FILTRATION RATE, and EDEMA. Kidney biopsy initially indicates focal segmental glomerular consolidation (hyalinosis) or scarring which can progress to globally sclerotic glomeruli leading to eventual KIDNEY FAILURE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Myo-inositol treatment ameliorated the decreased expression of ZO-1 and synaptopodin in an in vitro FSGS model, and as myo-inositol increased, myo-inositol oxygenase tissue expression decreased proportionally to eGFR." | 5.51 | Urinary myo-inositol is associated with the clinical outcome in focal segmental glomerulosclerosis. ( An, JN; Cho, JH; Choi, YW; Ha, H; Hwang, GS; Hyeon, JS; Jung, Y; Kim, DK; Kim, JH; Kwon, S; Lee, JP; Lee, SH; Oh, S; Park, SH; Yang, SH, 2019) |
| "Myo-inositol treatment ameliorated the decreased expression of ZO-1 and synaptopodin in an in vitro FSGS model, and as myo-inositol increased, myo-inositol oxygenase tissue expression decreased proportionally to eGFR." | 1.51 | Urinary myo-inositol is associated with the clinical outcome in focal segmental glomerulosclerosis. ( An, JN; Cho, JH; Choi, YW; Ha, H; Hwang, GS; Hyeon, JS; Jung, Y; Kim, DK; Kim, JH; Kwon, S; Lee, JP; Lee, SH; Oh, S; Park, SH; Yang, SH, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| An, JN | 1 |
| Hyeon, JS | 1 |
| Jung, Y | 1 |
| Choi, YW | 1 |
| Kim, JH | 1 |
| Yang, SH | 1 |
| Oh, S | 1 |
| Kwon, S | 1 |
| Lee, SH | 1 |
| Cho, JH | 1 |
| Park, SH | 1 |
| Ha, H | 1 |
| Kim, DK | 1 |
| Lee, JP | 1 |
| Hwang, GS | 1 |
1 other study available for inositol and Glomerulosclerosis, Focal Segmental
| Article | Year |
|---|---|
Urinary myo-inositol is associated with the clinical outcome in focal segmental glomerulosclerosis.
Topics: Adult; Aged; Biomarkers; Cell Line; Female; Glomerular Filtration Rate; Glomerulosclerosis, Focal Se | 2019 |